Stock Price & Analysis

Based on recent technical indicators and market sentiment, IDXX stock shows bearish signals with RSI at 47.44 indicating neutral to slightly oversold conditions, and recent analyst Jim Cramer expressing concerns about inconsistency. The stock's current downward trend and recent negative performance as the worst performer in the Nasdaq 100 suggests it would be prudent to avoid buying at current levels.

Based on the provided data and recent market trends, here's the price prediction for IDXX stock in 2025:

IDXX is expected to reach $450-460 by end of 2025, representing a ~7-10% upside from current levels around $419, driven by continued strength in companion animal diagnostics market despite near-term clinical visit headwinds.

The company's strategic focus on technology innovation and strong execution, evidenced by solid customer gains and growing premium installed base, supports this moderate growth projection.

Recent analyst consensus shows a cautiously optimistic outlook, with price targets ranging from $435 to $575, though several firms have lowered targets due to softer veterinary visit trends.

The S1 support level for IDXX Stock is $415.78 ,The R1 resistant level for IDXX Stock is $434.57.

As of the end of day on 2025-01-24, the price of IDXX Stock was $435.225.

The target price for IDXX Stock according to analyst rating is 492.50, with the highest price target at 559.00 and the lowest at 435.00. Analysts have a Moderate Buy rating on IDXX Stock overall.

The market cap of IDXX is $35.6B.

Based on the provided data and analysis, IDXX appears overvalued at current levels. The stock trades at elevated multiples with a P/E ratio of 48.75x and EV/EBITDA of 34.02x in Q3 2024, significantly above industry averages. Recent revenue growth has decelerated to 6% organic growth in Q3 2024, while U.S. clinical visits and end-market demand remain weak, leading to reduced full-year guidance. Multiple analysts have lowered their price targets, with JPMorgan cutting from $630 to $575 and Barclays reducing from $570 to $481. The stock has underperformed in 2024 with a -17.12% YTD return. Technical indicators show RSI at 47.44, suggesting neutral momentum but with MACD at -0.94 indicating bearish sentiment.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. Its Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. Its LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve the quality and safety of milk.

Based on the provided data and analysis, here is the price prediction for IDEXX Laboratories (IDXX) stock by 2030:

IDXX stock is projected to reach $750-800 by 2030, driven by continued growth in the companion animal diagnostics market and the company's strong market position. The expansion is supported by increasing pet ownership trends and rising veterinary care spending globally. Recent analyst reports indicate concerns about near-term clinical visit weakness but maintain long-term bullish outlook on IDEXX's niche market dominance.

IDXX has a total of 11000 employees.